Correlation Between Xenetic Biosciences and DiaMedica Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Xenetic Biosciences and DiaMedica Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xenetic Biosciences and DiaMedica Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Xenetic Biosciences and DiaMedica Therapeutics, you can compare the effects of market volatilities on Xenetic Biosciences and DiaMedica Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xenetic Biosciences with a short position of DiaMedica Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xenetic Biosciences and DiaMedica Therapeutics.

Diversification Opportunities for Xenetic Biosciences and DiaMedica Therapeutics

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between Xenetic and DiaMedica is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Xenetic Biosciences and DiaMedica Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DiaMedica Therapeutics and Xenetic Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xenetic Biosciences are associated (or correlated) with DiaMedica Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DiaMedica Therapeutics has no effect on the direction of Xenetic Biosciences i.e., Xenetic Biosciences and DiaMedica Therapeutics go up and down completely randomly.

Pair Corralation between Xenetic Biosciences and DiaMedica Therapeutics

Given the investment horizon of 90 days Xenetic Biosciences is expected to generate 3.37 times less return on investment than DiaMedica Therapeutics. In addition to that, Xenetic Biosciences is 1.36 times more volatile than DiaMedica Therapeutics. It trades about 0.03 of its total potential returns per unit of risk. DiaMedica Therapeutics is currently generating about 0.15 per unit of volatility. If you would invest  396.00  in DiaMedica Therapeutics on September 4, 2024 and sell it today you would earn a total of  138.00  from holding DiaMedica Therapeutics or generate 34.85% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Xenetic Biosciences  vs.  DiaMedica Therapeutics

 Performance 
       Timeline  
Xenetic Biosciences 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Xenetic Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting forward indicators, Xenetic Biosciences may actually be approaching a critical reversion point that can send shares even higher in January 2025.
DiaMedica Therapeutics 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Xenetic Biosciences and DiaMedica Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Xenetic Biosciences and DiaMedica Therapeutics

The main advantage of trading using opposite Xenetic Biosciences and DiaMedica Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xenetic Biosciences position performs unexpectedly, DiaMedica Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will offset losses from the drop in DiaMedica Therapeutics' long position.
The idea behind Xenetic Biosciences and DiaMedica Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

Equity Valuation
Check real value of public entities based on technical and fundamental data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance